Floatz logo

Nbi-921352

Focal Epilepsy

Neurocrine BiosciencesPhase 2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Focal Epilepsy cohort.

Asset / SponsorPhaseRating
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Oxcarbamezapine
Mario Negri Institute for Pharmacological Research
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A
Topamax
Mario Negri Institute for Pharmacological Research
Phase 4A

View all 50 →

Same molecule, other indications

Nbi-921352 is also rated in:

developmental and epileptic encephalopathy, 13Dormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →